Food Allergy Fund

08/20/2026

Omalizumab (Xolair) outperformed multiallergen OIT. But the headline numbers tell only part of the story.

36% of participants receiving omalizumab could tolerate a substantial amount of all three foods during a supervised food challenge, compared with 19% receiving multiallergen OIT.

The gap was driven largely by tolerability. Participants receiving multiallergen OIT experienced more adverse events and were more likely to leave the study before finishing.

Swipe to see how tolerability and completion shaped the result. 🔬

Want food allergy research explained clearly? Sign up for our Research Digest at the link in bio.

08/18/2026

Back-to-school safety isn’t only about plans and precautions. It’s also about helping children with food allergies feel understood.

Safe Kids. Strong Voices. - our free caregiver guide developed with insights from Dr. Becky - offers practical language for every adult supporting a child with food allergies.

For some children, taking the school bus feels safe and routine. For others, a child or parent may feel nervous, or a family may not feel confident that the child’s emergency plan can be carried out during the ride. Every child, family and school is different.

Swipe for language that can help in one of those moments.

Download the free guide through the link in our bio, and share it with someone who could use it this school year.

-to-School

08/14/2026

An allergy treatment being studied in children and teens takes a different approach: the treatment itself does not use whole peanut proteins.

Aravax’s investigational immunotherapy, PVX108, is made from seven synthetic peanut-peptide fragments. It is designed to target the T cells involved in peanut allergy while minimizing the risk of triggering acute reactions during treatment.

When Aravax co-founder and Chief Scientific Officer Dr. Sara Prickett presented PVX108 at the 2023 Food Allergy Fund Summit, its international Phase 2 trial had just begun.

Today, the trial is fully enrolled, PVX108 has received U.S. FDA Fast Track designation and Phase 2 results are expected later this year.

The results should help answer the questions that matter most: Can this approach meaningfully increase protection from peanut? And could that protection continue after treatment stops?

Swipe to see how PVX108 is designed to work and how the research has progressed.

08/13/2026

Some of the most ambitious food allergy research is looking beyond managing reactions to ask whether the underlying disease can be changed.

Join us in San Francisco to hear four leading Bay Area scientists explore that possibility. 🔔 Registration prices increase Aug. 15.

• Dr. Michael Fischbach, Stanford University
• Dr. Susan Lynch, UCSF
• Dr. Alexander Marson, Gladstone-UCSF
• Dr. Carlotta Ronda, Innovative Genomics Institute, UC Berkeley

Hear what they are learning, where the science could lead and what it will take to translate these discoveries into new approaches to food allergy.

We hope you can join us to connect with researchers, physicians, biotechnology leaders, patients and families working together to change the future of food allergy.

📍 The Commonwealth Club, San Francisco
📅 Oct. 21 | 4–6:30 p.m.

Register through the link in our bio.

08/11/2026

Thank you to Allergic Living for highlighting two studies supported by the Food Allergy Fund: the first human f***l microbiota transplantation study in adults with peanut allergy and a separate Phase 2 trial now underway in teens.

Together, the studies are examining whether changing the gut microbiome can help people become less reactive to peanut. Although the current trials focus on peanut allergy, the longer-term possibility is a microbiome-based treatment that could work across different food allergens.

FAF is proud to support Dr. Rima Rachid, Dr. Talal Chatila, Dr. Alexander Khoruts and their colleagues as they pursue this important research.

F***l transplant pills for food allergy are moving forward to a Phase 2 trial. Allergic Living speaks to lead researcher Dr. Rima Rachid on just published findings, plus new protocols for the awaited Phase 2 study in teens. They discuss the big hope: how this transplant process might make the allergic person's immune system accept an allergen like peanut (the first target). Read all about this intriguing research: https://www.allergicliving.com/2026/08/10/f***l-transplant-pills-for-peanut-allergy-advance-to-phase-2-trial/

Boston Children’s Hospital Food Allergy Fund

08/10/2026

New approaches to preventing and treating food allergy are moving into human trials and attracting major investment.

Meet three leaders driving that momentum at the Food Allergy Fund's inaugural Innovation Forum in San Francisco:

• Dr. Nikole Kimes, CEO of Siolta Therapeutics, Inc.. In its Phase 2 study, at-risk infants who completed a year of the company’s microbiome treatment had a 77% lower risk of being diagnosed with a food allergy than those who received a placebo.

• Dr. Uri Lopatin, CEO of Ukko. After raising $45 million, the company recently began testing its new peanut allergy immunotherapy in people.

• Dr. Brian Wong, former President and CEO of RAPT Therapeutics. The company developed a food allergy treatment being studied for dosing every two to three months and was acquired by GSK for $2.2 billion this year.

They will join scientists, clinicians, patients, families, entrepreneurs and investors on Oct. 21 to explore where the field is headed and what it will take to accelerate progress.

⏰ Register before prices increase Aug. 15 through the link in our bio.

Follow Food Allergy Fund for more on the science and innovation shaping the future of food allergy.

08/06/2026

⏰ Register Now: Ticket Prices Increase on August 15

Join us in San Francisco on Oct. 21 for the Food Allergy Fund's inaugural Innovation Forum. We’re bringing together leaders across science, biotechnology, and investment with food allergy families and patients to explore how advances in immunology, microbiome science, and biotechnology could lead to better prevention, treatment and a cure.

Register: https://foodallergyfund.org/faf-innovation-forum-sf

08/05/2026

Could changing the gut microbiome help treat food allergy? New research funded by the Food Allergy Fund offers encouraging early evidence.

Published today in Science Translational Medicine, the first human trial of f***l microbiota transplantation for food allergy offers encouraging early evidence.

Before treatment, all 15 adults in the study reacted to less than half a peanut. Four months after one treatment of 36 frozen capsules, 6 participants could tolerate more peanut before reacting.

Researchers also found important clues about why some people benefited, including changes in immune cells and how gut bacteria process bile acids.

This was a small, early-stage study, and larger trials are needed. But it provides proof of concept that changing the microbiome may offer a new path for treating food allergy.

FAF is proud to have helped fund the study, including its expansion and research into why some participants responded.

Swipe to learn how the treatment worked and what researchers are studying next.

Science Magazine

08/03/2026

Could a daily tablet that dissolves under the tongue help increase peanut tolerance?

That is one of the new studies featured in FAF's latest Food Allergy Research Digest.

This month, we look at encouraging peanut SLIT trial results, a comparison of XOLAIR and multi-allergen OIT, and new clues about how the gut microbiome may influence food allergy risk early in life.

We’re also highlighting new publications from FAF-funded scientists studying allergic immune pathways, sunflower seed allergy, eosinophilic gastritis and the impact of food allergy on children and caregivers.

Swipe to explore the findings, then read the full Research Digest at the link in our bio.

Share this with someone following food allergy research.

07/30/2026

For 13 days, children and teens showed us just how powerful their voices can be. ❤️

They carry their epinephrine. Read every label. Ask questions. Speak up for their siblings. Advocate for safer policies. And remind us why we're working toward a cure for food allergies.

To every child, teen and family who took part in 13 Days of Strong Voices: Thank you for sharing your stories, your courage and your hope with us.

The campaign may be over, but their voices will continue to move this work forward.

13 days of Strong Voices. One shared hope: a future without food allergies.

Help carry their voices and hope forward. Donate $13 to support food allergy research at foodallergyfund.org/give